JuglaninCAS# 5041-67-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 5041-67-8 | SDF | Download SDF |
PubChem ID | 5748554 | Appearance | Yellow powder |
Formula | C20H18O10 | M.Wt | 418.4 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Methanol : 16.67 mg/mL (39.85 mM; Need ultrasonic) | ||
Chemical Name | 3-[(2S,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one | ||
SMILES | C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(O4)CO)O)O)O | ||
Standard InChIKey | POQICXMTUPVZMX-WNJKXWAASA-N | ||
Standard InChI | InChI=1S/C20H18O10/c21-7-13-15(25)17(27)20(29-13)30-19-16(26)14-11(24)5-10(23)6-12(14)28-18(19)8-1-3-9(22)4-2-8/h1-6,13,15,17,20-25,27H,7H2/t13-,15+,17-,20+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Juglanin has anti-tumor, antioxidant,and hepatoprotective activities. Juglanin shows protective effects on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats. Juglanin can lead to G2/M phase arrest, induce apoptosis as well as autophagy through the ROS/JNK signaling pathway in human breast cancer cells |
Targets | TLR | MAPK | NF-kB | JAK | STAT | ROS | JNK |
In vivo | The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats.[Pubmed: 27261609]Biomedicine & Pharmacotherapy, 2016 ,81 :318-28.High fructose-feeding is an essential causative factor leading to the development and progression of hepatitis associated with high levels of endotoxin (LPS). Juglanin, as a natural compound extracted from the crude Polygonum aviculare, displayed inhibitory activity against inflammation response and cancer growth. However, researches about its role on anti-inflammation and apoptosis are far from available. |
Kinase Assay | Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion.[Pubmed: 27899257 ]Biomed Pharmacother. 2017 Jan;85:303-312.Breast cancer is one of the most common primary malignant tumors of among women, the long-term survival of which has stagnated in the past decades. Juglanin as a natural production mainly extracted from green walnut husks of Juglans mandshurica has been defined as the functional composition among a series of compounds. It showed powerful protective effect in various diseases by inhibiting inflammation and tumor cells growth. However, the effect of Juglanin on human breast cancer and the underlying mechanisms remains to be elucidated. |
Structure Identification | Arch Pharm Res. 2010 Feb;33(2):203-8.Two new C-glucosyl benzoic acids and flavonoids from Mallotus nanus and their antioxidant activity.[Pubmed: 20195819 ]
|
Juglanin Dilution Calculator
Juglanin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3901 mL | 11.9503 mL | 23.9006 mL | 47.8011 mL | 59.7514 mL |
5 mM | 0.478 mL | 2.3901 mL | 4.7801 mL | 9.5602 mL | 11.9503 mL |
10 mM | 0.239 mL | 1.195 mL | 2.3901 mL | 4.7801 mL | 5.9751 mL |
50 mM | 0.0478 mL | 0.239 mL | 0.478 mL | 0.956 mL | 1.195 mL |
100 mM | 0.0239 mL | 0.1195 mL | 0.239 mL | 0.478 mL | 0.5975 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3-Nitropropionic acid
Catalog No.:BCC6303
CAS No.:504-88-1
- DL-Homocysteic acid
Catalog No.:BCN2233
CAS No.:504-33-6
- 4-Aminopyridine
Catalog No.:BCC5267
CAS No.:504-24-5
- Orcinol
Catalog No.:BCN5612
CAS No.:504-15-4
- (-)-di-de-Omethylgrandisin
Catalog No.:BCN7872
CAS No.:50393-98-1
- Cyclo(Phe-Gly)
Catalog No.:BCN2431
CAS No.:5037-75-2
- Apixaban
Catalog No.:BCC2295
CAS No.:503612-47-3
- Pentamidine dihydrochloride
Catalog No.:BCC5194
CAS No.:50357-45-4
- glucagon receptor antagonists 1
Catalog No.:BCC1593
CAS No.:503559-84-0
- NU7441 (KU-57788)
Catalog No.:BCC3679
CAS No.:503468-95-9
- 3'-Galloylquercitrin
Catalog No.:BCN8254
CAS No.:503446-90-0
- N-Methylflindersine
Catalog No.:BCN3641
CAS No.:50333-13-6
- Isoliquiritin
Catalog No.:BCN5945
CAS No.:5041-81-6
- Isorhamnetin-3-O-beta-D-Glucoside
Catalog No.:BCN1247
CAS No.:5041-82-7
- 1,5,6-Trihydroxyxanthone
Catalog No.:BCN7642
CAS No.:5042-03-5
- Methyl 2alpha-hydroxyhardwickiate
Catalog No.:BCN7595
CAS No.:50428-93-8
- GW441756
Catalog No.:BCC5093
CAS No.:504433-23-2
- Araneosol
Catalog No.:BCN5613
CAS No.:50461-86-4
- Homopiperazine
Catalog No.:BCC8995
CAS No.:505-66-8
- 3-(Carboxymethylamino)propanoic acid
Catalog No.:BCN1791
CAS No.:505-72-6
- Fenspiride HCl
Catalog No.:BCC4659
CAS No.:5053-08-7
- Columbianadin
Catalog No.:BCN1275
CAS No.:5058-13-9
- Isojacareubin
Catalog No.:BCN6883
CAS No.:50597-93-8
- Arachidonic acid
Catalog No.:BCN2215
CAS No.:506-32-1
Two new C-glucosyl benzoic acids and flavonoids from Mallotus nanus and their antioxidant activity.[Pubmed:20195819]
Arch Pharm Res. 2010 Feb;33(2):203-8.
Two new 2-C-beta-D-glucopyranosyl benzoic acid derivatives named mallonanosides A (1) and B (2) were isolated from the methanolic extract of the leaves of Mallotus nanus along with five known flavonoids, kaempferin (3), Juglanin (4), quercitrin (5), myricitrin (6), and rhoifolin (7). Their structures were established on the basis of spectral and chemical evidence. Their antioxidant activities were shown to depend on the number of hydroxyl groups, and the location and species of sugar moiety.
The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats.[Pubmed:27261609]
Biomed Pharmacother. 2016 Jul;81:318-328.
High fructose-feeding is an essential causative factor leading to the development and progression of hepatitis associated with high levels of endotoxin (LPS). Juglanin, as a natural compound extracted from the crude Polygonum aviculare, displayed inhibitory activity against inflammation response and cancer growth. However, researches about its role on anti-inflammation and apoptosis are far from available. Here, it is the first time that Juglanin was administrated to investigate whether it inhibits fructose-feeding-induced hepatitis in rats and to elucidate the possible mechanism by which Juglanin might recover it. Fructose-feeding rats were orally administrated with Juglanin of 5, 10 and 20mg/kg for 6 weeks, respectively. Juglanin exerted prevention of fructose-feeding-stimulated increased LPS levels, accelerated alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) and up-regulated inflammatory cytokines expression in serum, mainly including tumor necrosis factor-alpha (TNF-a), Interleukin 1beta (IL-1beta), Interleukin 6 (IL-6) and Interleukin 18 (IL-18). Meanwhile, toll-like receptor 4 (TLR4)-modulated mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-kappaB) and apoptosis-related Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway are involved in the progression of hepatic injury and inflammation. And Juglanin was found to suppress fructose-feeding-induced activation of these signaling pathways compared with the model group administrated only with fructose. These results indicate that Juglanin represses inflammatory response and apoptosis via TLR4-regulated MAPK/NF-kappaB and JAK2/STAT3 signaling pathway respectively in rats with hepatitis induced by LPS for fructose-feeding. Treatment of Juglanin might be an effective therapeutic strategy for preventing hepatitis.
Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion.[Pubmed:27899257]
Biomed Pharmacother. 2017 Jan;85:303-312.
Breast cancer is one of the most common primary malignant tumors of among women, the long-term survival of which has stagnated in the past decades. Juglanin as a natural production mainly extracted from green walnut husks of Juglans mandshurica has been defined as the functional composition among a series of compounds. It showed powerful protective effect in various diseases by inhibiting inflammation and tumor cells growth. However, the effect of Juglanin on human breast cancer and the underlying mechanisms remains to be elucidated. We reported here that Juglanin could inhibit cell proliferation by leading to G2/M phase arrest. Exposure to Juglanin resulted in the activation of cleaved caspase -3, -8, and -9, indicating that Juglanin induced apoptosis. Autophagy occurred in Juglanin-treated cells as evidenced by formation of autophagosome and up-regulation of LC3B-II. The Juglanin-induced cell death was significantly restored by the combination of autophagy and apoptosis. Further, Juglanin also induced JNK activation and ROS production. The JNK inhibitor attenuated Juglanin-caused apoptosis and autophagy significantly while ROS scavenger could reverse them. In addition, the ROS scavenger also inhibited G2/M phase arrest and phosphorylated JNK. Of note, we found that Juglanin had the similar effects on breast cancer cells. Finally, Juglanin inhibited tumor growth in the mouse xenograft model in vivo. Together, our results suggested that Juglanin led to G2/M phase arrest, induced apoptosis as well as autophagy through the ROS/JNK signaling pathway in human breast cancer cells. Hence, Juglanin might be a promising candidate for development of anti-tumor drugs targeting breast cancer.